

Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma) Welcomes Deputy Chief Executive Officer, Investment Promotion and Facilitation of MIDA For Visit at Manufacturing Facilities in Bandar Baru Enstek

BANDAR BARU ENSTEK, NEGERI SEMBILAN, 11 November 2021 –Malaysia’s first multi-product commercial manufacturing facilities, Novugen Pharma Sdn Bhd and Novugen Oncology Sdn Bhd (formerly known as Oncogen Pharma), were visited by the Deputy Chief Executive Officer, Malaysian Investment Development Authority (MIDA), Mr. Sivasuriyamoorthy Sundara Raja together with his team on Thursday.

MIDA’s last visit took place on 18 March 2021, by the Deputy Chief Executive Officer II, Mr. Ahmad Khairuddin Abdul Rahim, accompanied by The Deputy Minister of International Trade and Industry (MITI), YB Senator Datuk Lim Ban Hong. Since then, the manufacturing facilities have seen vast progression with more machineries installed and team of professionals recruited to operate the plants.

Mr. Sivasuriyamoorthy Sundara Raja were welcomed by the CEO of Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma), Mr. Rahil Mahmood who expressed his gratitude to MIDA, “It is an honour to have Mr. Sivasuriyamoorthy Sundara Raja from MIDA together with the team, visiting our manufacturing facilities for the first time. I also wanted to add that we are very appreciative to MIDA, for all the support given in the last five years and helping us reaching the milestones we have accomplished.”

During the session, Mr. Rahil Mahmood have presented on the companies’ updates and other key topics that may impact the Malaysian economy. “Oncology and non-oncology drugs that are niche such as cardiovascular or diabetes are very expensive in the market as they are imported from abroad. With our R&D and manufacturing presence in Malaysia and being the first in ASEAN to have fully integrated facilities to develop both active pharmaceutical ingredient (API) and finished dosage form (FDF) products, we are bringing cost-effective solution in Malaysia and potentially other countries in the ASEAN region” said Mr. Rahil Mahmood.

Mr. Rahil Mahmood added, “with our strong R&D and manufacturing technology presence here in Malaysia, we are non-infringed to patents. Hence, we are capable to launch our products few years before the patent expires. The CEO of Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma) also shared, with their capabilities, they aim to put Malaysia on the map as a global manufacturing hub and an exporter of high-quality drugs by leveraging on the companies’ available technology and industry know-how.

“Our goal is to be a game changer in Malaysia’s healthcare landscape. In the country, 60% of our drugs were imported from other countries, especially those which are high valued drugs such as chronic care and cancer treatment. Hence, manufacturing these drugs locally, narrows Malaysia’s foreign deficit. Additionally, we target to catapult the country to becoming a global player in the pharmaceutical landscape by exporting our products to over 75 countries.”

Today, Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma) have started to expand their horizon worldwide. “Apart from Malaysia, our manufacturing is present in Uzbekistan with state-of-the-art facilities fitted with advanced pharmaceutical process equipment, engineered to the

highest quality & safety standards. As part of our effort to support the manufacturing facilities in Uzbekistan, our scientists from Malaysia's office visit the country every year to perform technology transfer processes."

The companies' milestones were applauded by Mr. Sivasuriyamoorthy Sundara Raja who expressed his pride and enthusiasm for the companies' accomplishments in Malaysia and global pharmaceutical industry. He also proposed ideas to further promote the companies' brand and emphasized on MIDA's strategic collaboration to support Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma) goals by creating a business eco-system, from talent sourcing to media relations and other business transactions.

-ENDS-



Delegations during the tour of Novugen Pharma manufacturing facilities



Delegations during the tour of Novugen Oncology (formerly known as Oncogen Pharma) manufacturing facilities.



Group photo of Mr. Sivasuriyamoorthy Sundara Raja (4th from right), Mr Rahil Mahmood (5th from right).

About Novugen

Novugen is a wholly owned subsidiary company of a UAE based group with more than 30 years of experience in strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's globally minded strategy, synergistic approach and wealth of experience enable us to respond to the complex challenge of bringing hard-to-source and technology-intensive products to market while maintaining affordable pricing and rigorous quality assurance. As a technology leader, we create efficiency by integrating our total value chain. At Novugen, our science and business teams work together seamlessly to innovate new concepts and fresh ideas to accelerate the launch of pharmaceuticals that lack robust generic alternatives due to their complexity.

Website: www.novugen.com